Skip to main content
SpringerLink
Log in

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience

  • Nephrology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction

Chronic hepatitis C infection is common among patients on dialysis. While the associated liver disease is usually relatively mild during dialysis, disease progression can accelerate due to immunosuppression following kidney transplantation, and interferon therapy after transplantation stimulates graft rejection. Pegylated interferon and ribavirin are now the recommended treatment for chronic hepatitis C virus in patients without renal failure. However, until now, there has been relatively little information on the efficacy and tolerability of pegylated interferon in dialysis patients.

Aim of the work

To evaluate the response to pegylated interferon alpha-2a in chronic hepatitis C–infected patients on chronic hemodialysis.

Patients and methods

This controlled study included 28 patients with end-stage renal disease who had been on dialysis in the Prince Salman Center for Kidney Disease for more than 6 months and tested positive for HCV RNA on repeated occasions. Thirteen patients were treated with pegylated interferon alpha-2a therapy (of which three were also receiving ribavirin), and the remaining fifteen served as controls. Viral genotyping and both qualitative and quantitative PCR were carried out before starting therapy. Treatment was continued for 48 weeks. After 24 weeks of treatment, the biochemical and virological responses were evaluated. Biochemical response was evaluated at the end of the treatment, with sustained virological response (SVR) being evaluated 24 weeks later. The side effects were monitored throughout the treatment period.

Results

All patients in the treatment group completed 48 weeks of therapy without any drop out. Their mean age was 43.38 ± 11.62 years. After 24 weeks of therapy, 10 patients (76%) were initial responders, while 3 patients (24%) were resistant. Six months after termination of therapy, 9 patients (69%) were sustained responders, while one patient relapsed. Their ALT and AST dropped from 55.78 ± 33.79 IU/dl and 34.04 ± 19.58 IU/dl before starting therapy to 27.22 ± 16.54 IU/dl and 18.88 ± 12.28 IU/dl after termination (P = .06 and .08, respectively). Their mean hemoglobin (Hb) level dropped from 11.05 ± 1.43 to 9.48 ± 1.24 g/dl (P = 0.3), and white blood cell count (WBC) dropped from 6.82 ± 2.6 × 103/mm3 to 4.1 ± 2.34 × 103/mm3; (P = 0.57). Platelet count fell from 194.56 ± 129.78 × 103/mm3 to (152.33 ± 107.66 × 103/mm3; P = 0.39). When initial responders (n = 10) were compared to resistant patients (n = 3), the only observable difference was higher ALT and AST levels in resistant patients. Pegylated interferon alpha-2a was well tolerated, and none of the patients stopped interferon because of hematological side effects while dose modification was carried out in most of the patients. All three patients who received combination therapy from the start were sustained responders. None of the patients in the control group seroconverted to HCV negative status during the study period.

Conclusion

Pegylated interferon alpha-2a was well tolerated among our hemodialysis patients. Hematological disturbances appeared to be the most important adverse effects. At the end of therapy a response rate of up to 76%, with 69% sustained response, can be obtained with pegylated interferon alpha-2a therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aldrees A, Paul TT, Abu-Aisha H et al (1991) Cost evaluation of hemodialysis in ministry of health hospitals, Saudi Arabia: a NKF study. Saudi Kidney Dis Transplant Bull 2:125–133

    Google Scholar 

  2. Tokars JI, Miller ER, Alter MJ et al (1998) National surveillance of dialysis associated disease in the United States. ASAIO J 44:98–107

    Article  PubMed  CAS  Google Scholar 

  3. Saudi Center for Organ Transplantation Annual Report (2006) www.scot.org.sa

  4. Karkar A (2007) Hepatitis C in dialysis units: The Saudi experience. Hemodialysis Int 11:354–367

    Article  Google Scholar 

  5. Pereira BJG, Levey AS (1997) Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 51:981–989

    Article  PubMed  CAS  Google Scholar 

  6. Norder H, Bergstrom A, Uhnoo I et al (1998) Confirmation of nosocomial transmission of hepatitis C virus by phylogenetic analysis of the NS5-B region. J Clin Microbiol 36:3066–3069

    PubMed  CAS  Google Scholar 

  7. Roth D (1995) Hepatitis C virus: the nephrologist’s view. Am J Kidney Dis 25:3–16

    Article  PubMed  CAS  Google Scholar 

  8. Afsar B, Elsurer R, Sezer S et al (2009) Quality of life in hemodialysis patients: hepatitis C virus infection makes sense Int Urol Nephrol 41:1011–1019

    Google Scholar 

  9. Legendre C, Garrigue V, Le Bihan C et al (1998) Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65:667–670

    Article  PubMed  CAS  Google Scholar 

  10. Knodell RG, Ishak KG, Black WC et al (1981) Formulation ‘and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 5:431–435

    Article  Google Scholar 

  11. Mousa DH, Abdalla AH, Al-Shoail G et al (2004) Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Tranplant Proc 36:1831–1834

    Article  CAS  Google Scholar 

  12. Ayoola EA, Huraib S, Arif M et al (1991) Prevalence and significance of antibodies to hepatitis C virus among Saudi hemodialysis patients. J Med Virol 35:155–159

    Article  PubMed  CAS  Google Scholar 

  13. Hussein MM, Mooij JM, Roujouleh H et al (1994) Observations in a Saudi-Arabian dialysis population over a 13-year period. Nephrol Dial Transplant 9:1072–1076

    PubMed  CAS  Google Scholar 

  14. Karkar A, Abdulrahman MR, Ghacha R et al (2006) Prevention of viral hepatitis in hemodialysis units: the value of isolation. Saudi J Kidney Dis Transplant 17:183–188

    Google Scholar 

  15. Espinosa M, Martin-Malo A, Alvarez de Lara MA et al (2001) Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 16:1669–1674

    Article  PubMed  CAS  Google Scholar 

  16. Cruzado JM, Casanovas-Taltavull T, Torras J et al (2003) Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3:357–360

    Article  PubMed  CAS  Google Scholar 

  17. Bruchfeld A, Wilczek H, Elinder CG (2004) Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 78:745–750

    Article  PubMed  Google Scholar 

  18. Kamar N, Toupance O, Buchler M et al (2003) Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14:2092–2098

    Article  PubMed  CAS  Google Scholar 

  19. Meyers CM, Seeff LB, Stehman-Breen CO et al (2003) Hepatitis C and renal disease: un update. Am J Kidney Dis 42:631–657

    Article  PubMed  Google Scholar 

  20. Lamb MW, Marks IM, Modi MW MW et al (2001) Peg interferon alfa-2a (40 kD) (Pegasys) can be administered safely in patients with end-stage renal disease (abstract). Hepatology 34:326

    Google Scholar 

  21. Sporea I, Sirli R, Golea O et al (2004) Peg-interferon alfa-2a (40 kD) in patients on chronic haemodialysis with chronic hepatitis C. Preliminary results. Rom J Gastroenterol 13:99–102

    PubMed  Google Scholar 

  22. Teta D, Landtwing L, Üscher B, Gonvers J-J et al. (2005) Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 20:991–993

    Google Scholar 

  23. Kokoglu OF, Uc¸mak H, Hosoglu S et al (2006) Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21:575–580

    Article  PubMed  CAS  Google Scholar 

  24. Martin P, Mitra S, Farrington K et al (2000) Pegylated (40ku) Interferon alpha 2a (Pegasys) is unaffected by renal impairment (Abstract). Hepatology 32:842

    Article  Google Scholar 

  25. Al-Harbi ASB, Malik GH, Subaity Y et al (2005) Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transplant. 16:293–297

    Google Scholar 

  26. Sporea I, Popescu A, Sirli R et al. (2006) Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis treatment. J Gastroenterol 14(26):4191–4194

    Google Scholar 

  27. Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F et al (2004) Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.Aliment. Pharmacol. Ther 20:37–44

    CAS  Google Scholar 

  28. Dienstag JL, McHutchison JG (2006) American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130:225–230

    Article  PubMed  Google Scholar 

  29. Covic A, Maftei ID, Mardare NG et al. (2006) Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 19(6):794–801

    Google Scholar 

  30. Bruchfeld A, Lindahl K, Reichard O et al (2006) Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 13:316–321

    Article  PubMed  CAS  Google Scholar 

  31. Rendina M, Schena A, Castellaneta NM et al (2007) The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kD) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 46:768–774

    Article  PubMed  CAS  Google Scholar 

  32. Bruchfeld A, Stahle L, Andersson J et al (2001) Ribavirin treatment in dialysis patients with chronic hepatitis C infection: a pilot study. J Viral Hepatitis 8:287–292

    Article  CAS  Google Scholar 

  33. Russo MW, Ghalib R, Sigal S et al (2006) Randomized trial of pegylated interferon a-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21:437–443

    Article  PubMed  CAS  Google Scholar 

  34. Bruchfeld A, Lindahl K, Reichard O et al (2006) Pegylated interferon and ribavirin in hemodialysis patients. Nephrol Dial Transplant 21:1444–1445

    Article  PubMed  CAS  Google Scholar 

  35. Sabry AA, El-Dahshan KF, Mahmoud KM, El-Husseini A (2009) Effect of HCV infection on hematocrit and hemoglobin level in Egyptian hemodialysis patients. Int Urol Nephrol 41(1):189–193

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are very grateful to Michelle Chambers, Primary Care Mental Health Worker, Nottingham City NHS, UK, for the revision of the manuscript.

Author information

Authors and Affiliations

  1. Prince Salman Center for Kidney Disease, Riyadh, Kingdom of Saudi Arabia

    Khalid Alsaran & Naila Shaheen

  2. Mansoura Urology and Nephrology Center, Mansoura University, Mansoura, Egypt

    Alaa Sabry

Authors
  1. Khalid Alsaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alaa Sabry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naila Shaheen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Khalid Alsaran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alsaran, K., Sabry, A. & Shaheen, N. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience. Int Urol Nephrol 43, 865–873 (2011). https://doi.org/10.1007/s11255-010-9756-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-010-9756-1

Keywords

Search

Navigation